Oxford Biomedica (OXB) Share Price

Health Care Sector

  1. Home
    2. /
  2. Company
    3. /
  3. Oxford Biomedica

NOTE: This is based on 134 open tips for Oxford Biomedica (OXB)


Oxford Biomedica (OXB)
Latest Quote Price

421.50p

Oxford Biomedica (OXB)
Price Change (%)

-1.17%


Latest Bid : 420.50p Latest Ask : 422.50p
High Today : 429.00p Low Today : 412.50p
This Years High : 445.00p This Years Low : 167.20p
Volume : 86,942 MKT Cap : £443.63M
Trading Velocity : Premium Only Activity Score : Premium Only
Consensus Score : Premium Only Momentum Score : Premium Only

Stock Splits and Consolidations

30/05/2018 – Stock Consolidation 50.000:1.000


Oxford Biomedica (OXB) Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

Oxford Biomedica (OXB) Latest Tips

Type Tipster SectorScore Start date Performance
Neutral JP Morgan Premium Only 2024-12-03 05:25:00 03/12/2024 –
Neutral JP Morgan Premium Only 2024-10-28 04:58:00 28/10/2024 –
Hold Deutsche Bank Premium Only 2024-09-24 16:46:00 24/09/2024 0.13%
Outperform RBC Capital Premium Only 2024-05-21 15:16:00 21/05/2024 25.71%
Neutral JP Morgan Premium Only 2024-05-09 05:06:00 09/05/2024 –

Premium Content

You are missing Premium Content from this chart

Please Log In to a premium account or Sign Up today to view premium content.


Oxford Biomedica (OXB) Active Short Positions

Fund Manager Position Date
No active short positions

See more short positions...


Latest Bid : 420.50p Latest Ask : 422.50p
High Today : 429.00p Low Today : 412.50p
This Years High : 445.00p This Years Low : 167.20p
Volume : 86,942 MKT Cap : £443.63M

Oxford Biomedica Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.


Latest Oxford Biomedica Tips

Type Tipster SectorScore Start date Performance
Neutral JP Morgan Premium Only 2024-12-03 05:25:00 03/12/2024 –
Neutral JP Morgan Premium Only 2024-10-28 04:58:00 28/10/2024 –
Hold Deutsche Bank Premium Only 2024-09-24 16:46:00 24/09/2024 0.13%
Outperform RBC Capital Premium Only 2024-05-21 15:16:00 21/05/2024 25.71%
Neutral JP Morgan Premium Only 2024-05-09 05:06:00 09/05/2024 –

Stock Splits and Consolidations

30/05/2018 – Stock Consolidation 50.000:1.000